Study identification

PURI

https://redirect.ema.europa.eu/resource/22003

EU PAS number

EUPAS22002

Study ID

22003

Official title and acronym

Global Evaluation of the Interstitial Lung Disease Diagnostic Pathway (Global ILD-MDT study)

DARWIN EU® study

No

Study countries

Italy
United Kingdom

Study description

This two-phase study aims to characterise the global practice of diagnosing interstitial lung disease (ILD) and identify the features of ILD multidisciplinary team (MDT) meetings associated with more accurate diagnosis of ILD. Phase I is a global, standardised, systematic evaluation of the diagnostic process employed by a range of dedicated and non-dedicated ILD centres worldwide. An electronic questionnaire will be distributed through local leads, and national and international consortia. A pragmatic “strategic-opportunistic” approach will be taken, combining easily-scalable electronic data capture with local expertise to invite responses from a wide and representative range of (ultimately self-selecting) clinics and centres.Phase II is a global MDT ILD case review and diagnosis study to assess the diagnostic agreement across ILD MDTs and assess the diagnostic accuracy of ILD MDTs. Appropriate definition of these Phase II design components will be critical to the robustness and relevance of the study. The Phase II definition of an MDT, and the study’s geographical scope and case mix distribution, will aim to reflect real-life (as far as is practically possible) as established in Phase I. Centres identified in phase I will be invited to participate. Participants will be sent digitised reference cases, including pathology data, and diagnostic responses will be collected. Diagnostic accuracy will be determined against the diagnosis given by the reference case provider, against an expert MDT with global representation, and where possible, against the diagnostic inference of available follow up data.

Study status

Finalised
Research institutions and networks

Institutions

Multiple centres: 500 centres are involved in the study

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

Luca Richeldi

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Financial: Roche, Boehringer Ingelheim and Three Lakes Partnership, in kind: Veracyte
Study protocol
Initial protocol
English (889.77 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable